Log in to save to my catalogue

Durvalumab Immunotherapy

Durvalumab Immunotherapy

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2412999716

Durvalumab Immunotherapy

About this item

Full title

Durvalumab Immunotherapy

Publisher

Pittsburgh: Oncology Nursing Society

Journal title

Clinical journal of oncology nursing, 2020-06, Vol.24 (3), p.277-284

Language

English

Formats

Publication information

Publisher

Pittsburgh: Oncology Nursing Society

More information

Scope and Contents

Contents

Background: When resection is not an option, platinum-based chemoradiotherapy (CRT) has been the historic standard of care in non-small cell lung cancer (NSCLC). Prognosis remains poor with CRT alone. Durvalumab has shown significant improvement (versus placebo) in progression-free and overall survival in patients with unresectable stage III NSCLC...

Alternative Titles

Full title

Durvalumab Immunotherapy

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2412999716

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2412999716

Other Identifiers

ISSN

1092-1095

E-ISSN

1538-067X

DOI

10.1188/20.CJON.277-283

How to access this item